Methadone Pharmacogenetics

被引:96
|
作者
Kharasch, Evan D. [1 ,2 ]
Regina, Karen J. [1 ]
Blood, Jane [1 ]
Friedel, Christina [1 ]
机构
[1] Washington Univ, Dept Anesthesiol, Div Clin & Translat Res, St Louis, MO 63110 USA
[2] Washington Univ, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA
基金
美国国家卫生研究院;
关键词
CYTOCHROME P4503A CYP3A; CHRONIC NONCANCER PAIN; HUMAN LIVER-MICROSOMES; N-DEMETHYLATION; STEREOSELECTIVE METABOLISM; GENETIC POLYMORPHISMS; MAINTENANCE TREATMENT; OPIATE ADDICTS; UNITED-STATES; PLASMA-LEVELS;
D O I
10.1097/ALN.0000000000000867
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Background: Interindividual variability in methadone disposition remains unexplained, and methadone accidental overdose in pain therapy is a significant public health problem. Cytochrome P4502B6 (CYP2B6) is the principle determinant of clinical methadone elimination. The CYP2B6 gene is highly polymorphic, with several variant alleles. CYP2B6.6, the protein encoded by the CYP2B6*6 polymorphism, deficiently catalyzes methadone metabolism in vitro. This investigation determined the influence of CYP2B6*6, and other allelic variants encountered, on methadone concentrations, clearance, and metabolism. Methods: Healthy volunteers in genotype cohorts CYP2B6*1/*1 (n = 21), CYP2B6*1/*6 (n = 20), and CYP2B6*6/*6 (n = 17), and also CYP2B6*1/*4 (n = 1), CYP2B6*4/*6 (n = 3), and CYP2B6*5/*5 (n = 2) subjects, received single doses of IV and oral methadone. Plasma and urine methadone and metabolite concentrations were determined by tandem mass spectrometry. Results: Average S-methadone apparent oral clearance was 35 and 45% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. R-methadone apparent oral clearance was 25 and 35% lower in CYP2B6*1/*6 and CYP2B6*6/*6 genotypes, respectively, compared with CYP2B6*1/*1. R- and S-methadone apparent oral clearance was threefold and fourfold greater in CYP2B6*4 carriers. IV and oral R- and S-methadone metabolism was significantly lower in CYP2B6*6 carriers compared with that of CYP2B6*1 homozygotes and greater in CYP2B6*4 carriers. Methadone metabolism and clearance were lower in African Americans in part because of the CYP2B6*6 genetic polymorphism. Conclusions:CYP2B6 polymorphisms influence methadone plasma concentrations, because of altered methadone metabolism and thus clearance. Genetic influence is greater for oral than IV methadone and S- than R-methadone. CYP2B6 pharmacogenetics explains, in part, interindividual variability in methadone elimination. CYP2B6 genetic effects on methadone metabolism and clearance may identify subjects at risk for methadone toxicity and drug interactions.
引用
收藏
页码:1142 / 1153
页数:12
相关论文
共 50 条
  • [1] Pharmacogenetics of Methadone Response
    Francina Fonseca
    Marta Torrens
    Molecular Diagnosis & Therapy, 2018, 22 : 57 - 78
  • [2] Pharmacogenetics of Methadone Response
    Fonseca, Francina
    Torrens, Marta
    MOLECULAR DIAGNOSIS & THERAPY, 2018, 22 (01) : 57 - 78
  • [3] Pharmacogenetics of methadone therapy for drug addiction
    Shi, R. Z.
    Lim, M.
    Piacentine, L.
    Amen, S.
    Etter, M. L.
    Eichhorst, J.
    Kapur, K.
    Jannetto, P. J.
    Lehotay, D. C.
    Risinger, R. C.
    Wong, S. H.
    CLINICAL CHEMISTRY, 2006, 52 (06) : A72 - A72
  • [4] Pharmacogenetics of Methadone for Pain Management in Palliative Care
    Irwin, Madison N.
    Ellingrod, Vicki L.
    Smith, Michael A.
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2022, 63 (01) : E142 - E145
  • [5] ABCB / haplotype and OPRM / 118A > G genotype interaction in methadone maintenance treatment pharmacogenetics
    Barratt, Daniel T.
    Coller, Janet K.
    Hallinan, Richard
    Byrne, Andrew
    White, Jason M.
    Foster, David J. R.
    Somogyi, Andrew A.
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 : 53 - 62
  • [6] Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy
    Robinson, Katherine M.
    Eum, Seenae
    Desta, Zeruesenay
    Tyndale, Rachel F.
    Gaedigk, Andrea
    Crist, Richard C.
    Haidar, Cyrine E.
    Myers, Alan L.
    Samer, Caroline F.
    Somogyi, Andrew A.
    Zubiaur, Pablo
    Iwuchukwu, Otito F.
    Whirl-Carrillo, Michelle
    Klein, Teri E.
    Caudle, Kelly E.
    Donnelly, Roseann S.
    Kharasch, Evan D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (04) : 932 - 938
  • [7] Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone
    Kazi, Intishar
    Chenoweth, Meghan J.
    Jutras-Aswad, Didier
    Ahamad, Keith
    Socias, M. Eugenia
    Le Foll, Bernard
    Tyndale, Rachel F.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (03) : 506 - 514
  • [8] Methadone is methadone
    Denning, Denise J.
    CANADIAN FAMILY PHYSICIAN, 2021, 67 (02) : 81 - 84
  • [9] Methadone pharmacogenetics in vitro and in vivo: Metabolism by CYP2B6 polymorphic variants and genetic variability in paediatric disposition
    Wang, Pan-Fen
    Sharma, Anshuman
    Montana, Michael
    Neiner, Alicia
    Juriga, Lindsay
    Reddy, Kavya Narayana
    Tallchief, Dani
    Blood, Jane
    Kharasch, Evan D.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 88 (11) : 4881 - 4893
  • [10] PHARMACOGENETICS
    KALOW, W
    POSTGRADUATE MEDICINE, 1967, 42 (01) : 32 - &